Navigation Links
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Date:9/21/2009

ROCKVILLE, Md., Sept. 21 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

Neuralstem is the first company to commence a stem cell trial to treat ALS. The trial will study the safety of Neuralstem's cells and the surgical procedures and devices required for multiple injections of Neuralstem's cells directly into the grey matter of the spinal cord. The FDA's approval represents a significant step toward delivering regenerative medicine directly to damaged neural cells in humans. ALS affects roughly 30,000 people in the U.S., with about 7,000 new diagnoses per year.

Neuralstem CEO and President, Richard Garr, stated, "The beginning of our clinical trial program is a major step towards achieving Neuralstem's goal of treating ALS, a fatal neurodegenerative disease for which currently there is no effective treatment or cure. While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process. This trial will be in the extremely capable hands of Dr. Eva L. Feldman, M.D., Ph.D., Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery, and Dr. Jonathan Glass, Director of the Emory Neuromuscular Laboratory and Director of the Emory ALS Center, world
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neuralstem Shares Accepted for Trading on Amex(R)
2. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
3. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Neuralstem Sues StemCells, Inc. Over New Patent
6. Neuralstem Responds to New StemCells, Inc. Lawsuit
7. Neuralstem Fills Key Product Development Position
8. Neuralstem Reports Second Quarter Financial Results and Highlights
9. Neuralstem CEO to Speak on ALS Panel at World Stem Cell Summit
10. Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent
11. Neuralstem to Present at the 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
(Date:12/24/2014)... PharmaBoardroom,s new report, , ... available for free download , digs deep into this ... in the sector today. One area where ... in developing a homegrown pharmaceutical manufacturing base, even if the ... some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 /PRNewswire/ ... study of mazindol in children with attention deficit/hyperactivity disorder ... December 2014 . The paper, titled ... attention deficit/hyperactivity disorder" ( Konofal et al, ... eCollection 2014 ) shows that mazindol might be ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) ... Letter on January 13, 2009, indicating that it no ... forth in Nasdaq Marketplace Rule 4350(c)(1) (the "Rule"). The ... Director, which was announced publicly in a January 6, ...
... Healthcare ProfessionalsVOORHEES, N.J., Jan. 20 Current education about ... several reasons. The epidemiology of CDI is changing and ... disease. In addition, the epidemic strain continues to ... the United States and worldwide. To address the ...
... TaiGen Biotechnology Co., Ltd., a privately-held pharmaceutical ... diseases, cancer and diabetes-related complications, announced that it ... placement of preferred C stock from its existing ... Development Fund, YFY group, Taiwan Sugar Corporation, Yao-Hwa ...
Cached Biology Technology:Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1) 2Clostridium difficile Infection: Current Challenges and Controversies 2TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing 2
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... A scientist at the University of Liverpool will lead a ... ,baker,s yeast, to further understanding of how living cells function. ... body, such as cell cycle proteins and signalling proteins, were ... species of budding yeast, thought to have been originally isolated ...
... MADISON, WI, February 16, 2009 -- Grasslands in the ... be increasingly converted to growing bioenergy grain crops. Questions ... soil during the CRP program by perennial grasses if ... the potential effectiveness of no-till production systems to conserve ...
... quarter-century of data reveals how changing weather patterns and ... a heavy toll on penguin numbers NEW ... of Science for release 5p.m. EST Friday, Feb. 12, ... pollution, and other factors have conspired to drive penguin ...
Cached Biology News:Scientists study full protein content of 'baker's yeast' 2Will large amounts of soil carbon be released if grasslands are converted to energy crops? 2Penguins marching into trouble 2